SILO PHARMA, INC. Cost of Revenue
SILO PHARMA, INC. (SILO) reported Cost of Revenue of $20.69 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-13
- SILO PHARMA, INC. cost of revenue for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- SILO PHARMA, INC. cost of revenue for the quarter ending 2026-03-31 was $20.69K, a 1316.99% increase year-over-year.
- SILO PHARMA, INC. cost of revenue for the quarter ending 2025-12-31 was $20.69K, a 1317.05% increase year-over-year.
- SILO PHARMA, INC. cost of revenue for the quarter ending 2025-09-30 was $20.69K, a 1317.89% increase year-over-year.
- SILO PHARMA, INC. cost of revenue for fiscal 2023 was $5.84K, a 0.00% change from fiscal 2022.
- SILO PHARMA, INC. cost of revenue for fiscal 2022 was $5.84K, a 16.67% increase from fiscal 2021.
- SILO PHARMA, INC. cost of revenue for fiscal 2021 was $5.00K.
| Period end | Cost of Revenue 3 month | Cost of Revenue 3 month as first filed | Cost of Revenue 6 month | Cost of Revenue 6 month as first filed | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $20.69K 10-Q · filed 2026-08-13 | $41.38K derived: sum of 3 quarters · filed 2026-08-13 | $62.06K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $20.69K 10-Q · filed 2026-05-14 | $41.38K derived: sum of 2 quarters · filed 2026-05-14 | $62.06K derived: sum of 3 quarters · filed 2026-05-14 | $63.52K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | $20.69K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | $41.38K derived: sum of 2 quarters · filed 2026-04-14 | $42.84K derived: sum of 3 quarters · filed 2026-08-13 | $44.30K POS AM · filed 2026-04-14 | ||
| 2025-09-30 | $20.69K 10-Q · filed 2025-11-13 | $22.15K derived: sum of 2 quarters · filed 2026-08-13 | $23.61K 10-Q · filed 2025-11-13 | $25.07K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $1.46K 10-Q · filed 2026-08-13 | $2.92K 10-Q · filed 2026-08-13 | $4.38K derived: sum of 3 quarters · filed 2026-08-13 | $5.84K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $1.46K 10-Q · filed 2026-05-14 | $2.92K derived: sum of 2 quarters · filed 2026-05-14 | $4.38K derived: sum of 3 quarters · filed 2026-05-14 | $5.84K derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $1.46K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | $2.92K derived: sum of 2 quarters · filed 2026-04-14 | $4.38K derived: sum of 3 quarters · filed 2026-04-14 | $5.84K POS AM · filed 2026-04-14 | ||
| 2024-09-30 | $1.46K 10-Q · filed 2025-11-13 | $2.92K derived: sum of 2 quarters · filed 2025-11-13 | $4.38K 10-Q · filed 2025-11-13 | $5.84K derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $1.46K 10-Q · filed 2025-08-13 | $2.92K 10-Q · filed 2025-08-13 | $4.38K derived: sum of 3 quarters · filed 2025-08-13 | $5.84K derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $1.46K 10-Q · filed 2025-05-09 | $2.92K derived: sum of 2 quarters · filed 2025-05-09 | $4.38K derived: sum of 3 quarters · filed 2025-05-09 | $5.84K derived: sum of 4 quarters · filed 2025-05-09 | ||
| 2023-12-31 | $1.46K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $2.92K derived: sum of 2 quarters · filed 2025-03-28 | $4.38K derived: sum of 3 quarters · filed 2025-03-28 | $5.84K 10-K · filed 2025-03-28 | ||
| 2023-09-30 | $1.46K 10-Q · filed 2024-11-12 | $2.92K derived: sum of 2 quarters · filed 2024-11-12 | $4.38K 10-Q · filed 2024-11-12 | $5.84K derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $1.46K 10-Q · filed 2024-08-13 | $2.92K 10-Q · filed 2024-08-13 | $4.38K derived: sum of 3 quarters · filed 2024-08-13 | $5.84K derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $1.46K 10-Q · filed 2024-05-13 | $2.92K derived: sum of 2 quarters · filed 2024-05-13 | $4.38K derived: sum of 3 quarters · filed 2024-05-13 | $5.84K derived: sum of 4 quarters · filed 2024-05-13 | ||
| 2022-12-31 | $1.46K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $2.92K derived: sum of 2 quarters · filed 2024-03-25 | $4.38K derived: sum of 3 quarters · filed 2024-03-25 | $5.84K 10-K · filed 2024-03-25 | ||
| 2022-09-30 | $1.46K 10-Q · filed 2023-11-13 | $2.92K derived: sum of 2 quarters · filed 2023-11-13 | $4.38K 10-Q · filed 2023-11-13 | $5.84K derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $1.46K 10-Q · filed 2023-08-11 | $2.92K 10-Q · filed 2023-08-11 | $4.38K derived: sum of 3 quarters · filed 2023-08-11 | $5.84K derived: sum of 4 quarters · filed 2023-08-11 | ||
| 2022-03-31 | $1.46K 10-Q · filed 2023-05-12 | $2.92K derived: sum of 2 quarters · filed 2023-05-12 | $4.38K derived: sum of 3 quarters · filed 2023-05-12 | $5.84K derived: sum of 4 quarters · filed 2023-05-12 | ||
| 2021-12-31 | $1.46K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $2.92K derived: sum of 2 quarters · filed 2023-03-24 | $4.38K derived: sum of 3 quarters · filed 2023-03-24 | $5.00K 10-K · filed 2023-03-24 | ||
| 2021-09-30 | $1.46K 10-Q · filed 2022-11-10 | $2.92K derived: sum of 2 quarters · filed 2022-11-10 | $3.54K 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $1.46K 10-Q · filed 2022-08-01 | $38.50K 10-Q · filed 2021-08-13 | $2.08K 10-Q · filed 2022-08-01 | $70.45K 10-Q · filed 2021-08-13 | ||
| 2021-03-31 | $625.00 10-Q · filed 2022-05-13 | $31.95K 10-Q · filed 2021-05-17 | ||||
| 2020-06-30 | $1.33K 10-Q · filed 2021-08-13 | $1.42K 10-Q · filed 2021-08-13 | ||||
| 2020-03-31 | $84.00 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |